Drug intelligence / Profile preview

naphazoline hydrochloride + pheniramine maleate + panthenol

Development stage: Preclinical
Lead developer: EMS
Modality: Small Molecules
Administration: Intranasal

Overview

A combination drug containing naphazoline hydrochloride (a decongestant), pheniramine maleate (an antihistamine), and panthenol (provitamin B5). Naphazoline works by constricting blood vessels to reduce congestion, while pheniramine blocks histamine effects to relieve itching. Panthenol likely provides moisturizing and healing properties. This combination appears to be formulated as a nasal spray for treating nasal congestion and nasopharyngeal symptoms associated with upper respiratory allergies, flu, and colds.

Targets

ADRA1A (α1A)ADRA2A (α2A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on naphazoline hydrochloride + pheniramine maleate + panthenol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naphazoline hydrochloride + pheniramine maleate + panthenol.

Explore the full profile